Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Targacept to get $2M from AZ
November 2007
SHARING OPTIONS:

WINSTON-SALEM, N.C.—Targacept Inc., a clinical-stage biopharma developing a new class of drugs called NNR Therapeutics, has announced that AstraZeneca has secured an option for an exclusive license to Targacept's product candidate TC-5619 under terms of an existing collaboration agreement. As a result, AstraZeneca will make a $2 million payment to Targacept. Neuronal nicotinic receptors (NNRs) are a class of receptors found in the nervous system that play a critical role in modulating the release of neurotransmitters to regulate nervous system activity. The alpha7 NNR subtype has been shown in animal studies to be a key regulator of cognitive function. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.